Was this calculator helpful?
Formula Sources & References
Understanding PVR — Pulmonary Vascular Resistance in Clinical Practice
Pulmonary vascular resistance is one of the most important hemodynamic parameters in cardiology, critical care, and pulmonology. It tells clinicians how hard the right ventricle must work to push blood through the lungs — and elevated PVR is a key marker for pulmonary hypertension, right heart failure, and some of the most complex decisions in cardiovascular medicine, including transplant candidacy.
The concept is intuitive: PVR is the pressure difference across the pulmonary circuit divided by the blood flow going through it. When pulmonary vessels are healthy and open, resistance is low and the right ventricle operates at relatively modest pressures. When those vessels narrow, stiffen, or become blocked, resistance rises and the right ventricle must compensate — sometimes to the point of failure.
Normal PVR Values and Reference Ranges
| Parameter | Normal Range | Units | Clinical Significance |
|---|---|---|---|
| PVR | 37–250 | dynes·sec·cm⁻⁵ | Standard unit in most catheterization labs |
| PVR | 0.5–3.0 | Wood units (mmHg·min/L) | Preferred in pulmonary hypertension literature |
| PVRI | 255–285 | dynes·sec·cm⁻⁵·m² | Body surface area-indexed; used in pediatrics and transplant |
| SVR (comparison) | 800–1200 | dynes·sec·cm⁻⁵ | Approx 10× higher than PVR; left-sided circuit |
| mPAP (normal) | 9–18 | mmHg | PH defined as mPAP > 20 mmHg (2022 ESC/ERS guidelines) |
| TPG (normal) | <12 | mmHg | Transpulmonary gradient = mPAP − PAWP |
PVR in Pulmonary Hypertension Classification
The 2022 ESC/ERS guidelines redefined pulmonary hypertension as mPAP > 20 mmHg at rest (previously ≥ 25 mmHg). Within that definition, PVR is critical for subcategorization. Pre-capillary pulmonary hypertension (Group 1 PAH, Group 3 lung disease, Group 4 CTEPH) is defined by PVR > 2 Wood units with normal PAWP (≤ 15 mmHg). Post-capillary pulmonary hypertension (Group 2, left heart disease) has elevated PAWP (> 15 mmHg). This distinction drives completely different treatment approaches.
What Causes Elevated PVR?
- Pulmonary arterial hypertension (PAH): Idiopathic, heritable, or drug/toxin-induced; progressive vasoconstriction and vascular remodeling
- Hypoxia: Hypoxic pulmonary vasoconstriction — seen in COPD, altitude sickness, sleep apnea; protective mechanism redirecting blood from poorly ventilated areas
- Pulmonary embolism: Physical obstruction of pulmonary vessels raises resistance acutely
- Left heart disease: Elevated PAWP from mitral valve disease or LV dysfunction causes secondary pulmonary venous hypertension
- Interstitial lung disease: Parenchymal destruction reduces cross-sectional area of pulmonary vasculature
- Mechanical ventilation: High PEEP and lung overdistension compress alveolar vessels and raise PVR
- Polycythemia: Increased blood viscosity elevates resistance throughout the vascular tree
- Increased sympathetic tone: Catecholamine release causes pulmonary vasoconstriction
PVR in Transplant and Surgical Decision-Making
PVR is a critical criterion for heart transplant candidacy. Most centers use PVR > 5 Wood units as a contraindication, since the donated right ventricle cannot immediately adapt to very high pulmonary resistance. Specific thresholds: transpulmonary gradient (mPAP − PAWP) > 15 mmHg and PVRI > 6 Wood units·m² are used in formal transplant evaluation. For borderline values, vasodilator challenge testing during right heart catheterization tests pulmonary vascular reactivity and helps predict post-transplant outcomes.
Reducing Elevated PVR — Treatment Overview
Treatment depends entirely on the mechanism. For pre-capillary PAH, pulmonary vasodilators — including phosphodiesterase-5 inhibitors (sildenafil, tadalafil), endothelin receptor antagonists (bosentan, ambrisentan), and prostacyclin analogs (epoprostenol, treprostinil) — directly target the vasculature. For hypoxia-related elevation, supplemental oxygen is the most effective intervention. For CTEPH (Group 4), pulmonary thromboendarterectomy is the preferred curative treatment. In ICU patients, inhaled nitric oxide and prostacyclin serve as short-term PVR reducers.